BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 30417521)

  • 21. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
    Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
    Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
    Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
    Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
    Schneider F; Hoster E; Unterhalt M; Schneider S; Dufour A; Benthaus T; Mellert G; Zellmeier E; Bohlander SK; Feuring-Buske M; Buske C; Braess J; Fritsch S; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Hiddemann W; Spiekermann K
    Blood; 2009 May; 113(21):5250-3. PubMed ID: 19279329
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Patel K; Ganan-Gomez I; Jabbour E; Kadia T; Ravandi F; DiNardo C; Borthakur G; Takahashi K; Konopleva M; Komrokji RS; DeZern A; Kuzmanovic T; Maciejewski J; Pierce S; Colla S; Sekeres MA; Kantarjian H; Bueso-Ramos C; Garcia-Manero G
    Blood Adv; 2019 Mar; 3(6):922-933. PubMed ID: 30902805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
    Jain P; Kantarjian H; Patel K; Faderl S; Garcia-Manero G; Benjamini O; Borthakur G; Pemmaraju N; Kadia T; Daver N; Nazha A; Luthra R; Pierce S; Cortes J; Ravandi F
    Leuk Lymphoma; 2014 Jun; 55(6):1337-44. PubMed ID: 24004182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
    Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
    Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
    Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK
    J Clin Oncol; 2013 Nov; 31(32):4123-31. PubMed ID: 24062403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.
    Liu YR; Zhu HH; Ruan GR; Qin YZ; Shi HX; Lai YY; Chang Y; Wang YZ; Lu D; Hao L; Li JL; Li LD; Jiang B; Huang XJ
    Leuk Res; 2013 Jul; 37(7):737-41. PubMed ID: 23601747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trisomy 11 as an isolated abnormality in acute myeloid leukemia is associated with unfavorable prognosis but not with an NPM1 or KIT mutation.
    Alseraye FM; Zuo Z; Bueso-Ramos C; Wang S; Medeiros LJ; Lu G
    Int J Clin Exp Pathol; 2011 Apr; 4(4):371-7. PubMed ID: 21577323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.
    Papadopoulou V; Schoumans J; Basset V; Solly F; Pasquier J; Blum S; Spertini O
    Hematology; 2023 Dec; 28(1):2180704. PubMed ID: 36815747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
    Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
    Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.